"Cholesterol, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
| Descriptor ID |
D008078
|
| MeSH Number(s) |
D04.210.500.247.808.197.244 D10.532.515.500 D10.570.938.208.275 D12.776.521.550.500
|
| Concept/Terms |
Cholesterol, LDL- Cholesterol, LDL
- Low Density Lipoprotein Cholesterol
- beta-Lipoprotein Cholesterol
- Cholesterol, beta-Lipoprotein
- beta Lipoprotein Cholesterol
- LDL Cholesterol
|
Below are MeSH descriptors whose meaning is more general than "Cholesterol, LDL".
Below are MeSH descriptors whose meaning is more specific than "Cholesterol, LDL".
This graph shows the total number of publications written about "Cholesterol, LDL" by people in this website by year, and whether "Cholesterol, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 3 | 5 |
| 1996 | 0 | 3 | 3 |
| 1997 | 2 | 1 | 3 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 3 | 3 |
| 2000 | 3 | 7 | 10 |
| 2001 | 2 | 9 | 11 |
| 2002 | 1 | 5 | 6 |
| 2003 | 5 | 4 | 9 |
| 2004 | 2 | 6 | 8 |
| 2005 | 5 | 2 | 7 |
| 2006 | 4 | 4 | 8 |
| 2007 | 6 | 6 | 12 |
| 2008 | 5 | 15 | 20 |
| 2009 | 7 | 6 | 13 |
| 2010 | 3 | 3 | 6 |
| 2011 | 1 | 7 | 8 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 4 | 6 |
| 2014 | 3 | 6 | 9 |
| 2015 | 0 | 10 | 10 |
| 2016 | 0 | 3 | 3 |
| 2017 | 1 | 4 | 5 |
| 2018 | 5 | 5 | 10 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 4 | 5 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 8 | 8 |
| 2024 | 2 | 1 | 3 |
| 2025 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholesterol, LDL" by people in Profiles.
-
A prometabolite strategy inhibits cardiometabolic disease in an ApoE-/- murine model of atherosclerosis. JCI Insight. 2025 Aug 08; 10(15).
-
Estimated Theoretical Benefit of Aggressive LDL Lowering in Patients With Symptomatic Intracranial Atherosclerosis. Neurology. 2025 Jul 08; 105(1):e213768.
-
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025 05 17; 405(10491):1757-1768.
-
Small dense low-density lipoprotein cholesterol and coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis. Eur J Prev Cardiol. 2024 Jun 03; 31(8):1048-1054.
-
Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib. J Clin Pharmacol. 2024 Sep; 64(9):1150-1164.
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
-
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Curr Atheroscler Rep. 2024 02; 26(2):35-44.
-
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2023 10; 43(10):e404-e442.
-
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
-
Understanding the molecular mechanisms of statin pleiotropic effects. Arch Toxicol. 2023 06; 97(6):1529-1545.